BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to announce that its common shares will commence trading on the Toronto Stock Exchange as of the opening of trading on Friday, December 31, 2021.
December 29, 2021
· 3 min read